PTAB Holds Its Grounds In Post-SAS Tyvaso Review
The U.S. Patent Trial and Appeal Board on Tuesday stood by its decision to review all challenged grounds in two of United Therapeutics' patents covering its hypertension drug Tyvaso, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article